1. Home
  2. GLQ vs HBIO Comparison

GLQ vs HBIO Comparison

Compare GLQ & HBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Clough Global Equity Fund Clough Global Equity Fund of Beneficial Interest

GLQ

Clough Global Equity Fund Clough Global Equity Fund of Beneficial Interest

HOLD

Current Price

$7.72

Market Cap

152.2M

Sector

Finance

ML Signal

HOLD

Logo Harvard Bioscience Inc.

HBIO

Harvard Bioscience Inc.

HOLD

Current Price

$7.95

Market Cap

26.5M

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
GLQ
HBIO
Founded
2005
1901
Country
United States
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Biotechnology: Laboratory Analytical Instruments
Sector
Finance
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
152.2M
26.5M
IPO Year
N/A
2000

Fundamental Metrics

Financial Performance
Metric
GLQ
HBIO
Price
$7.72
$7.95
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$18.00
AVG Volume (30 Days)
39.7K
16.7K
Earning Date
01-01-0001
05-12-2026
Dividend Yield
11.11%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$116,176,000.00
Revenue This Year
N/A
$4.77
Revenue Next Year
N/A
$8.55
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$7.27
$0.38
52 Week High
$8.75
$8.40

Technical Indicators

Market Signals
Indicator
GLQ
HBIO
Relative Strength Index (RSI) 30.14 64.75
Support Level $7.65 $5.91
Resistance Level $8.18 $8.40
Average True Range (ATR) 0.11 0.26
MACD -0.01 -0.06
Stochastic Oscillator 6.52 32.36

Price Performance

Historical Comparison
GLQ
HBIO

About GLQ Clough Global Equity Fund Clough Global Equity Fund of Beneficial Interest

Clough Global Equity Fund is a closed-end management investment company. Its investment objective is to provide a high level of total return. The Fund invests in the equity, equity-related securities, and fixed-income securities in both U.S. and non-U.S. markets.

About HBIO Harvard Bioscience Inc.

Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, products, and services that enable advances in life science applications, including research, drug and therapy discovery, bioproduction, and preclinical testing. The company organizes its product line into two product families: Cellular and Molecular Technologies (CMT) and Preclinical. The CMT product family supports molecular, cellular, organ, and organoid research, as well as bioproduction and in vitro testing, while the Preclinical product family provides products for preclinical research and testing, including data collection and analysis for safety and regulatory compliance. Its geographical segments include the Americas, Europe, Middle East and Africa, and Asia.

Share on Social Networks: